No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
HCAT240517P7500
- 0.87
- 0.000.00%
15min DelayTrading May 7 11:12 ET
0.00High0.00Low
0.00Open0.87Pre Close0 Volume112 Open Interest7.50Strike Price0.00Turnover115.48%IV-1.68%PremiumMay 17, 2024Expiry Date0.97Intrinsic Value100Multiplier8DDays to Expiry0.00Time Value100Contract SizeAmericanOptions Type-0.7440Delta0.2809Gamma6.08Leverage Ratio-0.0216Theta-0.0012Rho-4.52Eff Leverage0.0032Vega
Intraday
- 5D
- 1D
News
Analysts' Top Healthcare Picks: Health Catalyst (HCAT), Sartorius (GB:0NIQ)
Health Catalyst to Announce First Quarter 2024 Operating Results and Host Conference Call on Thursday, May 9, 2024
Health Catalyst(HCAT.US) Officer Sells US$12,250.55 in Common Stock
$Health Catalyst(HCAT.US)$ Officer Llewelyn Linda sold 2,005 shares of common stock on Apr 15, 2024 at an average price of $6.11 for a total value of $12,250.55.Source: Announcement What is statement
Benign Growth For Health Catalyst, Inc. (NASDAQ:HCAT) Underpins Stock's 25% Plummet
Unfortunately for some shareholders, the Health Catalyst, Inc. (NASDAQ:HCAT) share price has dived 25% in the last thirty days, prolonging recent pain.
HROW, HCAT and EGRX Are Among After Hour Movers
R1 RCM, Health Catalyst Downgraded as KeyBanc Reviews Health-tech Space
Comments
The recent insider purchase signals confidence in the company's future, despite its lack of profit over the past year. Insider ownership shows some alignment between management and smaller shareholders.
CEO & Director of Health Catalyst Daniel Burton Buys 3.2% More SharesDespite Health Catalyst's subdued growth projections, it trades at a P/S ratio similar to the industry, indicating investors' willingness to pay for exposure. However, this could lead to disappointment if the P/S falls in line with the growth outlook, potentially impacting share prices.
The stock is undervalued with a bright future outlook not yet reflected in the current price. Consider financial health before investing.
Despite Health Catalyst's shares moving up, the company's muted revenue growth estimates cast doubt on whether the current P/S ratio is justifiable, risking a possible decline.
Over the past year, insider activities in Health Catalyst show optimism for the company's future. The significant percentage of company shares held by insiders exhibits alignment between management and smaller shareholders.
1
Read more